Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel versus rituximab in severe progressive diffuse cutaneous systemic sclerosis
NL-OMON59112Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of rapcabtagene autoleucel in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by Novartis. Primary endpoint: rCRISS50 response at Week 52. Started Jan 2026; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NL-OMON59112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59112.